Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C W Marano

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
The American Journal of Physiology|November 1, 1992
Modulation of tumor necrosis factor-induced increase in renal (LLC-PK1) transepithelial permeabilityJ M Mullin, K V Laughlin, C W Marano, et al.
Journal of Cellular Physiology|May 1, 1997
Different size limitations for increased transepithelial paracellular solute flux across phorbol ester and tumor necrosis factor-treated epithelial cell sheetsJ M Mullin, C W Marano, K V Laughlin, et al.
Annals of the New York Academy of Sciences|February 24, 2001
Increased tight junction permeability can result from protein kinase C activation/translocation and act as a tumor promotional event in epithelial cancersJ M Mullin, K V Laughlin, N Ginanni, et al.
Biochimica Et Biophysica Acta|May 24, 1995
Sodium-independent carrier-mediated inositol transport in cultured renal epithelial (LLC-PK1) cellsL M Russo, C W Marano, M M Hagee, et al.
European Journal of Cell Biology|March 19, 1999
Activation of NF-kappaB is necessary for the restoration of the barrier function of an epithelium undergoing TNF-alpha-induced apoptosisA P Soler, C W Marano, M Bryans, et al.
The Annals of Thoracic Surgery|November 18, 2000
Plasma concentrations of soluble tumor necrosis factor receptor I and tumor necrosis factor during cardiopulmonary bypassC W Marano, L A Garulacan, K V Laughlin, et al.
Alimentary Pharmacology & Therapeutics|April 28, 2009
Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trialsG R Lichtenstein, R H Diamond, C L Wagner, et al.
Alimentary Pharmacology & Therapeutics|June 30, 2015
Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitisP Rutgeerts, B G Feagan, C W Marano, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
The American Journal of Physiology|November 1, 1992
Modulation of tumor necrosis factor-induced increase in renal (LLC-PK1) transepithelial permeabilityJ M Mullin, K V Laughlin, C W Marano, et al.
Journal of Cellular Physiology|May 1, 1997
Different size limitations for increased transepithelial paracellular solute flux across phorbol ester and tumor necrosis factor-treated epithelial cell sheetsJ M Mullin, C W Marano, K V Laughlin, et al.
Annals of the New York Academy of Sciences|February 24, 2001
Increased tight junction permeability can result from protein kinase C activation/translocation and act as a tumor promotional event in epithelial cancersJ M Mullin, K V Laughlin, N Ginanni, et al.
Biochimica Et Biophysica Acta|May 24, 1995
Sodium-independent carrier-mediated inositol transport in cultured renal epithelial (LLC-PK1) cellsL M Russo, C W Marano, M M Hagee, et al.
European Journal of Cell Biology|March 19, 1999
Activation of NF-kappaB is necessary for the restoration of the barrier function of an epithelium undergoing TNF-alpha-induced apoptosisA P Soler, C W Marano, M Bryans, et al.
The Annals of Thoracic Surgery|November 18, 2000
Plasma concentrations of soluble tumor necrosis factor receptor I and tumor necrosis factor during cardiopulmonary bypassC W Marano, L A Garulacan, K V Laughlin, et al.
Alimentary Pharmacology & Therapeutics|April 28, 2009
Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trialsG R Lichtenstein, R H Diamond, C L Wagner, et al.
Alimentary Pharmacology & Therapeutics|June 30, 2015
Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitisP Rutgeerts, B G Feagan, C W Marano, et al.
Pageof 2